• Alias: IMC-11F8
    • A recombinant human IgG1 EGFR monoclonal antibody that binds (with a high affinity) to the ligand binding site of the EGFR receptor to prevent receptor activation and downstream signaling.
    • FDA approved for metastatic squamous cell carcinoma of the lungs (NSCLC)
    • Recommended dose: 800 mg IV over 60 minutes on days 1 and 8 of a 3-week cycle in combination with gemcitabine/cisplatin until disease progression
    • Half-life: â™14 days
    • Side effects: Headache, rash (acneiform eruption), electrolyte imbalance (potassium, phosphorus, calcium, magnesium), diarrhea, vomiting, stomatitis
    Other topics in Targeted and Immunotherapy Agents